All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2021 TCT Meetings Digital Experience, the MPN Hub spoke to Ruben A. Mesa, UT Health San Antonio, San Antonio, US. We asked, When should we give JAK inhibitors to patients with myelofibrosis (MF) in the peri-transplant setting?
When should we give JAK inhibitors to patients with MF in the peri-transplant setting?
Points for discussion include whether the use of JAK inhibitors prior to transplant is helpful, whether to continue delivery throughout transplantation, and the benefit of using fedratinib as second line therapy.
Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?
The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San Antonio, US, during the 61st American Society of...
What are the promising new agents for patients with myelofibrosis?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What are the promising new agents for patients...
Subscribe to get the best content related to MPN delivered to your inbox